US OptionsDetailed Quotes
SGMT250117C12500
- 0.05
- 0.000.00%
15min DelayClose Jan 8 16:00 ET
0.05High0.05Low
0.05Open0.05Pre Close2 Volume0 Open Interest12.50Strike Price10.00Turnover316.64%IV133.71%PremiumJan 17, 2025Expiry Date0.00Intrinsic Value100Multiplier8DDays to Expiry0.05Extrinsic Value100Contract SizeAmericanOptions Type0.0557Delta0.0452Gamma107.40Leverage Ratio-0.0165Theta0.0001Rho5.98Eff Leverage0.0009Vega
Sagimet Biosciences Stock Discussion
📊⚡️📊
Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024
Sagimet Biosciences presented Phase 2b data for denifanstat, its fatty acid synthase (FASN) inhibitor, at AASLD 2024. The FASCINATE-2 trial showed significant improvement in liver fibrosis in high-risk MASH patients, particularly in the F3 population where 49% of denifanstat-treated patients showed improvement versus 13% for placebo. AI-ba...
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Ascletis Pharma has completed enrollment of 480 patients in its Phase III clinical trial of ASC40 (denifanstat), a once-daily oral tablet for treating moderate to severe acne. The randomized, double-blind, placebo-controlled trial began on January 24, 2024, with patients divided equally between treatment and placebo groups. The study will evalua...
Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions With FDA on the Development of Denifanstat for Mash; Phase 3 Program Initiation Expected by End of 2024
Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology
Sagimet Biosciences Inc. (Nasdaq: SGMT) announced the publication of results from their Phase 2b FASCINATE-2 clinical trial of denifanstat in The Lancet Gastroenterology & Hepatology. The trial, conducted on patients with biopsy-confirmed metabolic-dysfunction associated steatohep...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
Sagimet Biosciences Inc. (Nasdaq: SCMT)
announced that the FDA has granted Breakthrough Therapy designation to denifanstat for treating noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis.
This designation was supported by positive data from the Phase 2b FASCINATE-2 trial, where denifanstat showed statistically significant imp...
Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in Mash
No comment yet